Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

Open Access

Peer-reviewed

Research Article

James B. Koprich ,

* E-mail: j.koprich@atuka.com

Affiliations Atuka Inc., Toronto, Canada, Krembil Research Institute, University Health Network, Toronto, Canada
⨯
Tom H. Johnston,

Affiliations Atuka Inc., Toronto, Canada, Krembil Research Institute, University Health Network, Toronto, Canada
⨯
Gabriela Reyes,

Affiliation Krembil Research Institute, University Health Network, Toronto, Canada
⨯
Vanessa Omana,

Affiliation Krembil Research Institute, University Health Network, Toronto, Canada
⨯
Jonathan M. Brotchie

Affiliations Atuka Inc., Toronto, Canada, Krembil Research Institute, University Health Network, Toronto, Canada
⨯

Reader Comments (0)

Macaque
Is the Subject Area "Macaque" applicable to this article?

Thanks for your feedback.
Neurons
Is the Subject Area "Neurons" applicable to this article?

Thanks for your feedback.
Dopamine
Is the Subject Area "Dopamine" applicable to this article?

Thanks for your feedback.
Substantia nigra
Is the Subject Area "Substantia nigra" applicable to this article?

Thanks for your feedback.
Dopaminergics
Is the Subject Area "Dopaminergics" applicable to this article?

Thanks for your feedback.
Parkinson disease
Is the Subject Area "Parkinson disease" applicable to this article?

Thanks for your feedback.
Primates
Is the Subject Area "Primates" applicable to this article?

Thanks for your feedback.
Viral vectors
Is the Subject Area "Viral vectors" applicable to this article?

Thanks for your feedback.